Sort
82,697 grants matching “vaccine development”
Mechanisms of SIV suppression by CD8+ lymphocytes
$795,676Guido Silvestri · Emory University · R01 · FY2012 · AI
Translational Geroscience Network
$795,615James L. Kirkland · Cedars-Sinai Medical Center · R33 · FY2025 · AG
Advancing communication strategies to support future HIV vaccine use among African Americans in the South.
$795,497Tiarney D Ritchwood · Duke University · R01 · FY2023 · MD
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$795,460Ignacio E. Sanz · Emory University · U54 · FY2020 · CA
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$795,459Rafick-Pierre Sekaly · Emory University · U54 · FY2020 · CA
Immune Regulation in Mycobacterial and Fungal Infections
$795,335Daniel Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Defining functional humoral correlates of immunity to guide vaccine design
$795,292Facundo Damian Batista · Massachusetts General Hospital · R01 · FY2023 · AI
Pathogenic determinants of the SIV envelope transmembrane cytoplasmic domain
$795,242James A Hoxie · University Of Pennsylvania · R01 · FY2015 · AI
Phase I Trial for TB Therapeutics - VTEU
$795,222Emmanuel B Walter · Duke University · N01 · FY2015 · AI
Comprehensive antigenic mapping of the human anti-peanut IgE antibody response
$795,181Scott Alan Smith · Vanderbilt University Medical Center · R01 · FY2024 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies
$795,113George M Shaw · University Of Pennsylvania · R01 · FY2024 · AI
Natural Immunity Against Chlamydia trachomatis
$795,093Toni Darville · Univ Of North Carolina Chapel Hill · R01 · FY2020 · AI
Mechanisms of immunopathology of COVID-19/ARDS, and strategies to mitigate detrimental inflammatory responses
$795,038Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Immune Control and Evasion during Acute HCV Infection
$795,032Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2014 · AI
Immune Control and Evasion during Acute HCV Infection
$795,032Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2012 · AI
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization
$795,027Cynthia Ann Derdeyn · University Of Washington · R01 · FY2024 · AI
Marketability of a technology-based intervention to increase HPV vaccination.
$794,930Michael Hecht · Real Prevention, Llc · R44 · FY2017 · DP
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
$794,913Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2025 · AI
NKT cells as modulators of AIDS vaccine efficacy
$794,854Amitinder Kaur · Tulane University Of Louisiana · R01 · FY2015 · AI
COVID-19, Inflammation and HPA axis activity, and Risk for Psychopathology in Youth
$794,774Nadine M. Melhem · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · MH
Immune Dysfunction in HIV+ Opioid Users
$794,668Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2020 · DA
Epigenomic analysis of primary immune cells from young and old animals
$794,641Myong-Hee Sung · National Institute On Aging · ZIA · FY2017 · AG
Development of Efficacious and Stable Nasal Vaccine Formulations
$794,620Herman F. Staats · Duke University · U01 · FY2011 · AI
Host blood biomarkers for the diagnosis prognosis and treatment response of childhood TB
$794,603Mark Hatherill · University Of Cape Town · R01 · FY2023 · AI
Project 1: PREVENT Program Critical Path Project
$794,578Daniel Tuse · University Of Louisville · U19 · FY2015 · AI